Welcome to BioSeeker Group!

Analytical Tool - Antibodies and Peptides in Oncology

Additional Information

Published Date Feb 21, 2012
PDF Fact Sheet View Fact Sheet for the report Analytical Tool - Antibodies and Peptides in Oncology in PDF
Format PDF & Software Application
Publisher BioSeeker Group

Availability: In stock

€5,950.00

Quick Overview

A unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody and peptide cancer R&D and business development.
Request free sample pages from Analytical Tool - Antibodies and Peptides in Oncology

"Analytical Tool – Antibodies and Peptides in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the antibody and peptide cancer drug competitive landscape. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are four products already appreciated by many of our customers:


The Package Includes:

  • A progress analysis on current and emerging drugs
  • Information on most companies active in R&D
  • Information on key industry related projects
  • Data from most important clinical trials
  • Information on early developmental stage projects
  • Possibility of performing advanced searches suited to your individual needs


This Tool will Assist You in:

  • Tracking cutting edge companies, therapies and new technologies
  • Rapid identification of partners & competitors
  • Laying down a comprehensive framework for further analysis of the field
  • Producing presentations surrounding the development of antibody and peptide drugs in cancer
  • Identifying emerging products & key areas of pharmaceutical R&D

*This software application is a searchable database reflects the most recent advances in the field of antibody and peptide cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker’s software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.

Request free sample pages from Analytical Tool - Antibodies and Peptides in Oncology

Other selected research from the 'Analytical Tool' category:


Analytical Tool - Cancer Immunotherapy
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer immunotherapy. Learn More


Analytical Tool - Apoptosis in Oncology
In this Analytical Tool, BioSeeker Group brings light and understanding of the whole industrial endeavor in apoptosis as cancer therapeutic mechanism. Learn More

Other selected research from the 'Oncology' category:


Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?
This report comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. The report extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target profiles, and assesses them in 69 different cancer indications. Learn More


Triple Analysis: Leukemia, Lymphoma and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Cancer Vaccines. Learn More

Other selected research from the 'Biologicals' category:


Nucleic Acid Therapies in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 204 companies plus partners who are today developing 229 nucleic acid therapy drugs in 520 developmental projects in cancer across 173 different targets. In addition, there are 7 suspended drugs and another 177 drugs where development has been ceased. Learn More


Biosimilars and Follow-On Biologics: World Market 2011-2021
you will see how the market can develop How will the biosimilars and follow-on biologics market develop this decade? Our new report shows you that emerging industry and market’s... Learn More